Wilson Sonsini Goodrich & Rosati advised Nvelop Therapeutics on intellectual property matters related to the transaction. Chroma Medicine and Nvelop Therapeutics announced their merger and subsequent...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented AvenCell Therapeutics in the transaction, and Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction. AvenCell Therapeutics...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters on the deal. Verona Pharma plc (Nasdaq: VRNA) announced that the U.S. Food and Drug...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on the transaction. Constructive Bio, a pioneering synthetic genomics company, announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised FluoRok on patent matters related to the transaction. FluoRok, a deep-tech start-up focused on fluorochemical manufacturing, announced the completion of...
You must be a Standard 1 Year member to access this content.
Taft Stettinius & Hollister advised ONL Therapeutics on the transaction, and Wilson Sonsini Goodrich & Rosati advised the company on patent matters. ONL Therapeutics, Inc. announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised eGenesis on the transaction. eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Ochre Bio in the transaction. Ochre Bio, a pioneer in chronic liver disease medicine development, announced the start of a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Amber on the transaction. Amber Therapeutics, a UK-based medical technology company, announced it closed a Series A financing, raising $100...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Prime Medicine and Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction, while Davis Polk & Wardwell...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arena BioWorks on patent and transactional matters. Arena BioWorks announced its launch as a biomedical research institute with a mission...
You must be a Standard 1 Year member to access this content.
